Summit Therapeutics (SMMT) Receivables Refunds (2016 - 2024)
Summit Therapeutics filings provide 9 years of Receivables Refunds readings, the most recent being $557000.0 for Q4 2024.
- Quarterly Receivables Refunds fell 34.32% to $557000.0 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $557000.0 through Dec 2024, down 34.32% year-over-year, with the annual reading at $557000.0 for FY2024, 34.32% down from the prior year.
- Receivables Refunds hit $557000.0 in Q4 2024 for Summit Therapeutics, down from $660000.0 in the prior quarter.
- Across five years, Receivables Refunds topped out at $15.7 million in Q4 2021 and bottomed at $557000.0 in Q4 2024.
- Average Receivables Refunds over 5 years is $7.1 million, with a median of $6.3 million recorded in 2020.
- The largest annual shift saw Receivables Refunds soared 117.26% in 2021 before it plummeted 93.73% in 2023.
- Summit Therapeutics' Receivables Refunds stood at $9.9 million in 2020, then soared by 59.24% to $15.7 million in 2021, then crashed by 63.26% to $5.8 million in 2022, then crashed by 85.29% to $848000.0 in 2023, then crashed by 34.32% to $557000.0 in 2024.
- Per Business Quant, the three most recent readings for SMMT's Receivables Refunds are $557000.0 (Q4 2024), $660000.0 (Q3 2024), and $953000.0 (Q2 2024).